Evaluation of Left Ventricular Enlargement as a Marker of Early Disease in Familial Dilated CardiomyopathyClinical Perspective by Diane Fatkin, Thomas.

Slides:

Advertisements

Similar presentations

Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.

Advertisements

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Restrictive Physiology is a Major Predictor of Poor Outcomes in Children with Hypertrophic Cardiomyopathy Shiraz A Maskatia MD, Jamie A Decker MD, Joseph.

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,

Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Selumetinib vs Chemotherapy on Progression-Free.

Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Epidemiology and natural history of atrial fibrillation:

Fig ACCF/AHA Guideline for the management of heart failure

Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved.

by Michael D. Elliott, Ajoy Kapoor, Michele A. Parker, Dixon B

Copyright © 2002 American Medical Association. All rights reserved.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

Fig. 1 Splenomegaly and increased viral load in cardiac and splenic tissue during the progression of murine AIDS. Panel A: Upper panel–representative Hematoxylin.

Copyright © 2007 American Medical Association. All rights reserved.

Algorithm for guideline-directed medical therapy for patients with SIHD. Colors correspond to the class of recommendations in the ACCF/AHATable The.

Circ Cardiovasc Qual Outcomes

In Vivo Analysis of Troponin C Knock-In (A8V) MiceCLINICAL PERSPECTIVE

Circ Cardiovasc Interv

Trends in Medication Choices for Hypertension in the Elderly

Gulf Survey of Atrial Fibrillation Events (Gulf SAFE)‏

Circ Cardiovasc Qual Outcomes

Complexities of Genetic Testing in Familial Dilated Cardiomyopathy

Genome-Scale Methods Converge on Key Mitochondrial Genes for the Survival of Human Cardiomyocytes in HypoxiaClinical Perspective by Lindsay M. Edwards,

Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing.

Circ Cardiovasc Qual Outcomes

Choline Diet and Its Gut Microbe–Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload–Induced Heart FailureCLINICAL PERSPECTIVE by.

So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

Physician and Patient Influences on Provider Performance

Relative Distributions

Effect of Provider Volume on the Accuracy of Hospital Report Cards

Circ Arrhythm Electrophysiol

Box plot showing percentage change in early diastolic pulsed-Doppler mitral inflow (E)/early diastolic tissue Doppler velocity (E´) from pre– to post–balloon.

Supravalvular Aortic Stenosis

Quantitative Proteome Analysis Reveals Increased Content of Basement Membrane Proteins in Arteries From Patients With Type 2 Diabetes Mellitus and Lower.

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Circ Cardiovasc Interv

Effect of intervention on diastolic function.

Cardiac Remodeling in Obesity

Mathematical representation of Bayes theorem.

Circ Cardiovasc Qual Outcomes

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Integrated Metabolomics and Genomics

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Catheter-Based Treatment of Coronary Artery Disease

Developed in Collaboration With The American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

Joerg Herrmann, MD, Amir Lerman, MD, Nicole P

Nat. Rev. Cardiol. doi: /nrcardio

Cardiac support device, restrictive mitral valve annuloplasty, and optimized medical treatment: A multimodality approach to nonischemic cardiomyopathy

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

Carolyn Y. Ho et al. JCHF 2015;3:

Alan G. Japp et al. JACC 2016;67: Differentiation of Athlete’s Heart From Early DCM by Myocardial Deformation Imaging Two-dimensional speckle.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Douglas L. Mann, MD, Michael A. Acker, MD, Mariell Jessup, MD, Hani N

Fig. 2. Evidence-based medication prescriptions

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

Connie W. Tsao et al. JCHF 2016;4:

Pamela E. Scott et al. JACC 2018;71:

Classification of left ventricular (LV) size by (A) LV internal diameter in diastole (LVIDD) according to LV end-diastolic volume index (LVEDVi), (B) LVIDD.

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Connie W. Tsao et al. JCHF 2016;4:

Early surgical intervention versus watchful waiting and outcomes for asymptomatic severe aortic regurgitation Christophe de Meester, MS, Bernhard L.

β-Blocker Use for the Stages of Heart Failure

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Heritability estimates in percentages using structural equations modelling for primary trait phenotypes in DCM (LVEF and LVEDD), HCM (IVSd) and LQTS (QTc).

Receiver operating characteristic curve showing results for two selected models, applied to the testing cohort. Receiver operating characteristic curve.

Presentation transcript:

Evaluation of Left Ventricular Enlargement as a Marker of Early Disease in Familial Dilated CardiomyopathyClinical Perspective by Diane Fatkin, Thomas Yeoh, Christopher S. Hayward, Victoria Benson, Angela Sheu, Zara Richmond, Michael P. Feneley, Anne M. Keogh, and Peter S. Macdonald Circ Genom Precis Med Volume 4(4):342-348 August 16, 2011 Copyright © American Heart Association, Inc. All rights reserved.

Results of baseline screening and follow-up of asymptomatic relatives of patients with familial dilated cardiomyopathy (DCM). dFS indicates depressed left ventricular (LV) fractional shortening; and LVE, LV enlargement. *The outcomes of relatives with LVE (n=72) who were not receiving any treatment during the period between progress echocardiograms (“natural history” cohort) are indicated by the black lines. Results of baseline screening and follow-up of asymptomatic relatives of patients with familial dilated cardiomyopathy (DCM). dFS indicates depressed left ventricular (LV) fractional shortening; and LVE, LV enlargement. *The outcomes of relatives with LVE (n=72) who were not receiving any treatment during the period between progress echocardiograms (“natural history” cohort) are indicated by the black lines. Six of these individuals subsequently crossed over to the treatment group and underwent further follow-up. †Cardiovascular medications, including β-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists, were administered for various indications (DCM prophylaxis, hypertension, palpitations, atrial fibrillation) at some time during the follow-up period. Diane Fatkin et al. Circ Cardiovasc Genet. 2011;4:342-348 Copyright © American Heart Association, Inc. All rights reserved.

Receiver operating characteristic analysis of different methods for assessment of left ventricular (LV) dilation in asymptomatic relatives and healthy control subjects. Receiver operating characteristic analysis of different methods for assessment of left ventricular (LV) dilation in asymptomatic relatives and healthy control subjects. AUC indicates area under the curve; Framingham, criteria based on data from the Framingham Heart Study; LV end-diastolic diameter (LVEDD) differences from 95th percentile values are shown; NHLBI indicates criteria formulated by the National Heart, Lung, and Blood Institute expert panel; and LVEDD (% predicted), ratio of actual LVEDD to predicted diameter, expressed as a percentage. Diane Fatkin et al. Circ Cardiovasc Genet. 2011;4:342-348 Copyright © American Heart Association, Inc. All rights reserved.